Date	Event	Description
10 May 2017	New citation required and conclusions have changed	The original published review (Abrishami 2009) concluded that trials found no difference in the instance of unwanted effects between sugammadex and neostigmine. Our updated review concludes that sugammadex reduces the risk of adverse events when compared with neostigmine.
10 May 2017	New search has been performed	The original published review (Abrishami 2009) has been updated by new review authors and split into two reviews, one review comparing sugammadex and neostigmine, and the other comparing sugammadex and placebo, as well as different doses of sugammadex. This review compares sugammadex and neostigmine and has been updated as of 10 May 2017 with regard to the search. The new search added eight years of research and 38 new trials to this review, including three trials that compared sugammadex and neostigmine. In total, this review comprises 41 included studies as well as 3 studies awaiting classification and 20 ongoing studies. Furthermore, review authors have completely revised the current review methodologically in accordance with the latest recommendations from Cochrane, with incorporation of full risk of bias tables, summary of finding tables, and trial sequential analysis. For more details, see Differences between protocol and review and Published notes.